Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Lead Product(s): Bisantrene
Therapeutic Area: Oncology Product Name: RC220
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Race Oncology
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023